Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Acquire Molecular Dx Test Maker Artus for $39.2M

NEW YORK, May 31 (GenomeWeb News) - Qiagen will acquire Artus of Germany, a maker of PCR-based diagnostic tests, for approximately $39.2 million in cash, the company said today.

 

Artus, located in Hamburg, focuses on diagnostic tests based on PCR and RT-PCR for infectious disease detection, pharmacogenomics, and veterinary diagnostics. The company, founded in 1998 as a spin-off from the Bernhard-Nocht-Institute for Tropical Medicine in Hamburg, sells more than 60 assays to detect viral and bacterial pathogens and has distribution agreements with Abbott Laboratories and MWG Biotech.

 

Qiagen said in a statement that "this acquisition is a perfect fit in its strategy to increase Qiagen's value as a partner to the molecular diagnostics industry." The company expects the acquisition will add about $15 million in net sales and $1.5 million to $2 million in net income to its 2006 earnings.

 

Qiagen reported $380.6 million in revenues for its 2004 fiscal year.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.